NewAmsterdam Pharma (NAMS) details CAO exit, bonus and equity terms
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Severance duration: 12 months of base salary
Bonus treatment: Pro-rated 2026 annual bonus
Equity vesting extension: Through January 10, 2027
+1 more
4 metrics
Severance duration
12 months of base salary
Lump-sum payment under separation agreement
Bonus treatment
Pro-rated 2026 annual bonus
Based on target achievement through separation date
Equity vesting extension
Through January 10, 2027
Outstanding stock options and RSU awards
Option exercise deadline
February 10, 2027
Expiration of vested stock options exercise period
Key Terms
separation agreement, restricted stock unit, non-compete, release of claims
4 terms
separation agreement financial
"On April 24, 2026, Ms. Kooij and the Company entered into a separation agreement"
A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.
restricted stock unit financial
"outstanding stock options and restricted stock unit (“RSU”) awards through January 10, 2027"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
non-compete financial
"The Separation Agreement contains restrictive covenants, including confidentiality, non-compete and non-disparagement covenants"
A non-compete is a contract clause that prevents an employee, executive, or seller from working for or starting a rival business for a set time and area after leaving a company. It matters to investors because it protects the value of intellectual property, customer relationships and key personnel—like putting a temporary fence around a company’s customers and know‑how—while also creating legal and operational constraints that can affect talent mobility and deal attractiveness.
release of claims financial
"The Separation Agreement contains restrictive covenants ... and a release of claims"
FAQ
What did NewAmsterdam Pharma (NAMS) disclose about its Chief Accounting Officer?
NewAmsterdam Pharma disclosed that Chief Accounting Officer Louise Kooij will end her employment on August 31, 2026. The company entered into a separation agreement with her on April 24, 2026, outlining severance, bonus, equity vesting, and related covenants.
What severance payments will Louise Kooij receive from NewAmsterdam Pharma (NAMS)?
Louise Kooij is eligible for a lump-sum payment equal to twelve months of her current base salary. She will also receive a pro-rated 2026 annual cash bonus reflecting target achievement through her separation date, plus payment for accrued but unused holiday and vacation days under Dutch law.
How are NewAmsterdam Pharma (NAMS) equity awards for Louise Kooij treated in the separation agreement?
The separation agreement extends vesting of Louise Kooij’s outstanding stock options and RSU awards through January 10, 2027. In addition, the exercise period for each vested stock option she holds will expire on February 10, 2027, giving additional time to exercise vested options.
What restrictive covenants apply to Louise Kooij after leaving NewAmsterdam Pharma (NAMS)?
The separation agreement includes confidentiality, non-compete, and non-disparagement covenants, as well as a release of claims. These provisions are designed to govern Ms. Kooij’s conduct after her departure and to settle potential employment-related claims between her and the company.
When will NewAmsterdam Pharma (NAMS) file the full separation agreement with the SEC?
The company intends to file the full separation agreement with its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026. Investors will be able to review the complete terms once that report is submitted to the SEC.